VISCHER assisted LifeCare Partners (Switzerland) and LSP Life Sciences Partners (Netherlands) as lead investors in a CHF 15 million financing round of Kuros Biosurgery AG, a biotechnology company based in Zurich developing novel biomaterials and bioactive-biomaterial combination products and focused in therapeutic areas covering sealants and orthobiologics. An additional investment is expected in a second closing later this year. Kuros intends to use this financing to bring its lead sealant product, KUR-023, to market in Europe and the US and to further progress its lead orthobiologics product, KUR-111, into Phase III clinical studies. The team at VISCHER was led by Matthias Staehelin (Partner) with Moritz Jäggy (Associate), both Corporate.